NAFLD and NASH: Diagnosis, Risks, and Management Strategies

Added:

Weight-Neutral Management and Critique of Overmedicalization

While standard guidelines for NAFLD/NASH emphasize significant weight loss and emerging pharmacotherapies, an alternative perspective advocates for a weight-neutral approach and cautions against overmedicalization. Proponents of this view, including Health at Every Size (HAES) practitioners, argue that focusing primarily on weight loss is often unsustainable and can lead to weight cycling and stigma, which worsen metabolic health. Instead, they advocate for behavior-focused interventions—such as intuitive eating and joyful movement—to improve liver enzymes and metabolic health independently of weight change. Additionally, critics raise concerns about the overmedicalization of NAFLD (recently renamed MASLD). They argue that lowering diagnostic thresholds and aggressively promoting pharmaceutical treatments for early-stage, asymptomatic liver fat pathologizes a highly prevalent condition. This shift risks exposing millions of low-risk patients to expensive medications and side effects, driven partly by pharmaceutical interests, when public health strategies targeting broader socio-environmental factors would be safer and more effective.

Basic anatomy and physiological functions of the liver, particularly its role in nutrient metabolism and detoxification.
The concept of metabolic syndrome, including insulin resistance, obesity, dyslipidemia, and type 2 diabetes.
Fundamental lipid metabolism, specifically how the body stores, processes, and transports fats (triglycerides) in hepatocytes.
Basic pathology concepts of inflammation (steatosis vs. steatohepatitis) and the cellular response to tissue injury (fibrosis).
The progression of NASH to advanced liver disease, including liver cirrhosis, portal hypertension, and liver failure.
Emerging pharmacological treatments and clinical trials for NASH, such as THR-beta agonists, GLP-1 receptor agonists, and antifibrotic agents.
Advanced diagnostic technologies, specifically non-invasive biomarkers, transient elastography (FibroScan), and magnetic resonance elastography (MRE).
The development and pathophysiology of Hepatocellular Carcinoma (HCC) secondary to long-standing NASH.
Pediatric NAFLD/NASH, focusing on its unique epidemiology, risk factors, and pediatric-specific clinical guidelines.
12.3K views120likes37:20@americanliverOriginal Release: 2019-06-26

Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common cause of chronic liver disease in the United States, affecting 30-40% of adults and 10% of children, characterized by fat accumulation in the liver not caused by alcohol, which can progress to inflammation (NASH) and potentially cirrhosis; management focuses on lifestyle modifications including gradual weight loss (0.5-1 kg/week), dietary changes toward whole grains and healthy fats, and regular exercise, as there are currently no FDA-approved medications for treatment.